OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+23.64%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$312M
AUM Growth
+$312M
(+10%)
Cap. Flow
-$776K
Cap. Flow
% of AUM
-0.25%
Top 10 Holdings %
Top 10 Hldgs %
68.33%
Holding
49
New
15
Increased
5
Reduced
3
Closed
14
Top Buys
| 1 |
ABLX
Ablynx NV American Depositary Shares
ABLX
|
$10.5M |
| 2 |
Fennec Pharmaceuticals
FENC
|
$8.49M |
| 3 |
CRISPR Therapeutics
CRSP
|
$6.6M |
| 4 |
argenx
ARGX
|
$5.59M |
| 5 |
Nektar Therapeutics
NKTR
|
$4.78M |
Top Sells
| 1 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
$9.25M |
| 2 |
CytomX Therapeutics
CTMX
|
$8.18M |
| 3 |
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
|
$7.75M |
| 4 |
Theravance Biopharma
TBPH
|
$6.16M |
| 5 |
Synlogic
SYBX
|
$4.75M |
Sector Composition
| 1 | Healthcare | 94.46% |
| 2 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Axogen
AXGN
$743M
| $55.8M | 17.85% | 1,970,000 | – | – |
|
|
BPMC
2
DELISTED
Blueprint Medicines
BPMC
| $55.4M | 17.75% | 735,000 | – | – |
|
3
FibroGen
FGEN
$47.8M
| $17.1M | 5.46% | 360,000 | – | – |
|
|
LOXO
4
DELISTED
Loxo Oncology, Inc
LOXO
| $14.8M | 4.75% | 176,300 +46,300 | +36% | +$3.9M |
|
|
IMMU
5
DELISTED
Immunomedics Inc
IMMU
| $14.5M | 4.65% | 898,800 | – | – |
|
6
Codexis
CDXS
$246M
| $14.2M | 4.55% | 1,700,600 | – | – |
|
7
Xoma
XOMA
$392M
| $11.4M | 3.65% | 320,200 | – | – |
|
|
ABLX
8
DELISTED
Ablynx NV American Depositary Shares
ABLX
| $10.5M | 3.36% | +420,000 | New | +$10.5M |
|
|
CORI
9
DELISTED
Corium International, Inc.
CORI
| $10.2M | 3.26% | 1,060,000 +140,000 | +15% | +$1.35M |
|
10
Sangamo Therapeutics
SGMO
$157M
| $9.51M | 3.05% | 580,000 | – | – |
|
|
SBBP
11
DELISTED
Strongbridge Biopharma plc.
SBBP
| $9.06M | 2.9% | 1,250,000 +70,000 | +6% | +$507K |
|
|
12
Fennec Pharmaceuticals
FENC
$247M
| $8.49M | 2.72% | +846,900 | New | +$8.49M |
|
13
Agios Pharmaceuticals
AGIO
$2.19B
| $7.43M | 2.38% | 130,000 | – | – |
|
|
BOLD
14
DELISTED
Audentes Therapeutics, Inc
BOLD
| $6.65M | 2.13% | 210,000 +30,000 | +17% | +$950K |
|
|
15
CRISPR Therapeutics
CRSP
$4.71B
| $6.6M | 2.11% | +281,000 | New | +$6.6M |
|
|
CBAY
16
DELISTED
Cymabay Therapeutics
CBAY
| $6.12M | 1.96% | 665,000 | – | – |
|
17
Ardelyx
ARDX
$1.53B
| $5.94M | 1.9% | 900,000 +200,000 | +29% | +$1.32M |
|
|
FOMX
18
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $5.77M | 1.85% | 960,000 -182,000 | -16% | -$1.09M |
|
|
19
argenx
ARGX
$43.6B
| $5.59M | 1.79% | +88,500 | New | +$5.59M |
|
|
20
Nektar Therapeutics
NKTR
$568M
| $4.78M | 1.53% | +80,000 | New | +$4.78M |
|
21
Rocket Pharmaceuticals
RCKT
$354M
| $4.7M | 1.51% | 1,802,000 | – | – |
|
|
XLRN
22
DELISTED
Acceleron Pharma Inc.
XLRN
| $4.31M | 1.38% | 101,500 | – | – |
|
23
Ultragenyx Pharmaceutical
RARE
$2.89B
| $4.17M | 1.34% | +90,000 | New | +$4.17M |
|
|
AMRN
24
Amarin Corp
AMRN
$311M
| $3.45M | 1.1% | +860,000 | New | +$3.45M |
|
|
DERM
25
DELISTED
Dermira, Inc.
DERM
| $2.78M | 0.89% | +100,000 | New | +$2.78M |
|